Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer

Dr. Tagawa discusses the incidence and identification of FGFR alterations in bladder cancer, the approval and use of erdafitinib in the second-line setting for patients with advanced bladder cancer, and research directions with the FGFR inhibitor in the field.